A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Sponsor: Merck Sharp & Dohme LLC
A PHASE1 clinical study on Advanced Solid Tumors, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 12 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jun 2022 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Nov 2018 — Mar 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .